1. Optimising Hormone Therapy in Advanced Disease
Laurent Boccon-Gibod 
European Urology Supplements 
Volume 4, Issue 8, Pages (November 2005)
DOI: /j.eursup
Copyright © Terms and Conditions

2. Fig. 1
A PSA DT of <3 months is statistically significantly associated with time to PCa specific survival [16]. D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst ;95(18):1376–1383, by permission of Oxford University Press.
European Urology Supplements 2005 4, 21-29DOI: ( /j.eursup )
Copyright © Terms and Conditions

3. Fig. 2
A PSA DT of <3 months is statistically significantly associated with time to overall survival [16]. D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst ;95(18):1376–1383, by permission of Oxford University Press.
European Urology Supplements 2005 4, 21-29DOI: ( /j.eursup )
Copyright © Terms and Conditions

4. Fig. 3
Overall survival after early or deferred therapy is similar in both groups [64]. Permission to reproduce has been granted by American Society of Clinical Oncology, 2004.
European Urology Supplements 2005 4, 21-29DOI: ( /j.eursup )
Copyright © Terms and Conditions